Evolus’ (EOLS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Evolus (NASDAQ:EOLS) in a report released on Wednesday,Benzinga reports. They currently have a $27.00 target price on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Evolus in a research report on Tuesday.

Evolus Stock Up 4.8 %

EOLS opened at $14.13 on Wednesday. The company has a market capitalization of $894.71 million, a PE ratio of -15.53 and a beta of 1.32. The business has a 50-day moving average of $11.70 and a 200-day moving average of $13.75. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. Evolus has a fifty-two week low of $9.25 and a fifty-two week high of $17.82.

Institutional Trading of Evolus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sei Investments Co. grew its stake in shares of Evolus by 9.8% in the second quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock worth $367,000 after acquiring an additional 3,020 shares during the last quarter. Profund Advisors LLC acquired a new stake in Evolus in the 2nd quarter worth $130,000. Cubist Systematic Strategies LLC increased its holdings in shares of Evolus by 5.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 338,254 shares of the company’s stock worth $3,670,000 after purchasing an additional 18,157 shares during the period. Armistice Capital LLC acquired a new position in shares of Evolus during the second quarter valued at about $3,906,000. Finally, AQR Capital Management LLC lifted its position in shares of Evolus by 33.3% in the 2nd quarter. AQR Capital Management LLC now owns 72,007 shares of the company’s stock worth $781,000 after acquiring an additional 17,971 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.